Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study
Conclusion. Orelabrutinib-based regimens were efficacious and well-tolerated in patients with CNSL. These combined therapies offer a new potential therapeutic strategy for patients with CNSL.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Chemotherapy | Drugs & Pharmacology | Immunotherapy | Investigational New Drugs | Lymphoma | Men | Study